Summary

This position is field based, and the incumbent will travel approximately 80% of the time within the territory. Our Sales Consultant is responsible, under director level supervision, for initial and follow-up sales calls on prospective and current clients for all patients to explain the use of our Pain Management device, Pulsed Electro-Magnetic Field (PEMF), non-narcotic option for Veterans experiencing chronic/acute pain. Selling to VAs and VA Community Based Outpatient Clinics (CBOCs).

Job description

Position Summary

This position is field based, and the incumbent will travel approximately 80% of the time within the territory. Our Sales Consultant is responsible, under director level supervision, for initial and follow-up sales calls on prospective and current clients for all patients to explain the use of our Pain Management device, Pulsed Electro-Magnetic Field (PEMF), non-narcotic option for Veterans experiencing chronic/acute pain. Selling to VAs and VA Community Based Outpatient Clinics (CBOCs).

Essential Duties & Responsibilities

Performs initial and follow-up sales calls on prospective and current clients.
Conducts product in-services to current clients as needed.
Must be knowledgeable in all aspects of the use, operation and maintenance of system.
Must be knowledgeable in all aspects of competitor products.
Develops sales plan according to the objectives of the company.
Documents sales activity for supervisor.

Preferred Experience

One year of sales experience in the medical field
Familiarity with medical terminology as it pertains to pain management
Military veteran experience preferred, based on current business with national VA facilities

Requirements

One year of sales experience in the medical field
Familiarity with medical terminology as it pertains to pain management
Military veteran experience preferred
Travel approximately 80% of the time within the territory

Company overview

eGenesis is a pioneering biotechnology company founded in 2015 and headquartered in Cambridge, Massachusetts, that is revolutionizing the field of organ transplantation through xenotransplantation. The company leverages its proprietary multiplex gene editing and genome engineering platform to develop human-compatible (HuCo) organs and cells, specifically focusing on addressing the global organ shortage crisis. eGenesis's EGEN Platform utilizes advanced CRISPR-based technologies to perform three classes of genetic modifications on porcine organs: eliminating endogenous retroviruses to prevent cross-species infection, knocking out porcine genes that trigger immune rejection, and inserting human genes to improve compatibility. The company has achieved significant milestones including the world's first successful transplant of a genetically engineered porcine kidney into a living patient in March 2024, followed by additional successful procedures. With lead programs in kidney transplantation and islet cell transplantation for diabetes, eGenesis has raised over $265 million in funding and employs 51-200 professionals dedicated to transforming transplantation medicine and providing scalable solutions for patients suffering from end-stage organ failure.